684 related articles for article (PubMed ID: 28225753)
1. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
[TBL] [Abstract][Full Text] [Related]
2. An unexpected player in Gaucher disease: The multiple roles of complement in disease development.
Pandey MK; Grabowski GA; Köhl J
Semin Immunol; 2018 Jun; 37():30-42. PubMed ID: 29478824
[TBL] [Abstract][Full Text] [Related]
3. C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages.
Serfecz JC; Saadin A; Santiago CP; Zhang Y; Bentzen SM; Vogel SN; Feldman RA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576075
[TBL] [Abstract][Full Text] [Related]
4. C-X-C Motif Chemokine Ligand 9 and Its CXCR3 Receptor Are the Salt and Pepper for T Cells Trafficking in a Mouse Model of Gaucher Disease.
Magnusen AF; Rani R; McKay MA; Hatton SL; Nyamajenjere TC; Magnusen DNA; Köhl J; Grabowski GA; Pandey MK
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884512
[TBL] [Abstract][Full Text] [Related]
5. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.
Sun Y; Liou B; Ran H; Skelton MR; Williams MT; Vorhees CV; Kitatani K; Hannun YA; Witte DP; Xu YH; Grabowski GA
Hum Mol Genet; 2010 Mar; 19(6):1088-97. PubMed ID: 20047948
[TBL] [Abstract][Full Text] [Related]
6. The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin.
Sadik CD; Miyabe Y; Sezin T; Luster AD
Semin Immunol; 2018 Jun; 37():21-29. PubMed ID: 29602515
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
[TBL] [Abstract][Full Text] [Related]
8. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.
Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL
J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410
[TBL] [Abstract][Full Text] [Related]
9. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases.
Karsten CM; Köhl J
Immunobiology; 2012 Nov; 217(11):1067-79. PubMed ID: 22964232
[TBL] [Abstract][Full Text] [Related]
10. Complement C5a Receptor 1 Exacerbates the Pathophysiology of
Herrmann JB; Muenstermann M; Strobel L; Schubert-Unkmeir A; Woodruff TM; Gray-Owen SD; Klos A; Johswich KO
mBio; 2018 Jan; 9(1):. PubMed ID: 29362231
[TBL] [Abstract][Full Text] [Related]
11. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
[TBL] [Abstract][Full Text] [Related]
12. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.
Farfel-Becker T; Vitner EB; Kelly SL; Bame JR; Duan J; Shinder V; Merrill AH; Dobrenis K; Futerman AH
Hum Mol Genet; 2014 Feb; 23(4):843-54. PubMed ID: 24064337
[TBL] [Abstract][Full Text] [Related]
13. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
Carvelli J; Demaria O; Vély F; Batista L; Chouaki Benmansour N; Fares J; Carpentier S; Thibult ML; Morel A; Remark R; André P; Represa A; Piperoglou C; ; ; Cordier PY; Le Dault E; Guervilly C; Simeone P; Gainnier M; Morel Y; Ebbo M; Schleinitz N; Vivier E
Nature; 2020 Dec; 588(7836):146-150. PubMed ID: 32726800
[TBL] [Abstract][Full Text] [Related]
14. Glucosylceramide accumulation in microglia triggers STING-dependent neuroinflammation and neurodegeneration in mice.
Wang R; Sun H; Cao Y; Zhang Z; Chen Y; Wang X; Liu L; Wu J; Xu H; Wu D; Mu C; Hao Z; Qin S; Ren H; Han J; Fang M; Wang G
Sci Signal; 2024 Mar; 17(829):eadk8249. PubMed ID: 38530880
[TBL] [Abstract][Full Text] [Related]
15. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
[TBL] [Abstract][Full Text] [Related]
16. Induction of osteoclastogenesis in an in vitro model of Gaucher disease is mediated by T cells via TNF-α.
Mucci JM; Scian R; De Francesco PN; García FS; Ceci R; Fossati CA; Delpino MV; Rozenfeld PA
Gene; 2012 Nov; 509(1):51-9. PubMed ID: 23010424
[TBL] [Abstract][Full Text] [Related]
17. C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake
Silva de França F; Villas-Boas IM; Cogliati B; Woodruff TM; Reis EDS; Lambris JD; Tambourgi DV
Front Immunol; 2021; 12():652242. PubMed ID: 33936074
[TBL] [Abstract][Full Text] [Related]
18. Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1
Wang HA; Lee JD; Lee KM; Woodruff TM; Noakes PG
Skelet Muscle; 2017 Jun; 7(1):10. PubMed ID: 28571586
[TBL] [Abstract][Full Text] [Related]
19. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease.
Sun Y; Zhang W; Xu YH; Quinn B; Dasgupta N; Liou B; Setchell KD; Grabowski GA
PLoS One; 2013; 8(3):e57560. PubMed ID: 23520473
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2.
Zaal A; van Ham SM; Ten Brinke A
Immunol Lett; 2019 May; 209():45-52. PubMed ID: 30959077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
